Rank #1880CRVS

Corvus Pharmaceuticals, Inc.

$17.53

-3.10% (Daily)

Market Cap

$1.47B

Revenue

$N/A

Rank by MCap

#1880

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Richard A. Miller M.D.

Headquarters

South San Francisco, CA

Employees

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, ps...